
Opinion|Videos|June 16, 2025
Improving diversity in future clinical trials for mHSPC
Author(s)Quoc-Dien Trinh, MD, MPH
Enhancing diversity in mHSPC clinical trials requires community outreach, collaboration, and accessible care for underrepresented populations.
Advertisement
Episodes in this series

Improving Clinical Trial Diversity
Key Themes:
- A multistakeholder approach is required (patients, communities, clinicians, payers, industry).
- Community outreach initiatives are essential for building trust.
- A comprehensive approach is needed to address the barriers to participation.
- Bring clinical trial access directly into communities of color.
Key Points for Physicians:
- Support or participate in community outreach programs.
- Address practical barriers to clinical trial participation with patients.
- Consider geographical and logistical factors when referring patients to trials.
- Recognize the importance of building trust through community engagement.
Notable Insights: Creating direct conduits to high-quality care through community-based initiatives represents a practical strategy for improving trial diversity and addressing historical mistrust.
Clinical Significance: Systematic approaches to improving trial diversity are essential for generating evidence applicable to all patient populations and addressing historical health care disparities.
Advertisement
Related to this article

Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.

The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.

Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.

John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.

Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
Advertisement
Advertisement
Trending on Urology Times
1
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
2
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
3
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
4
Aglatimagene besadenovec shows sustained immune remodeling in localized prostate cancer
5



